N-(5-cyano-4-(isopropylthio)pyridin-2-yl)-7-formyl-6-((N-methylacetamido)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(5-cyano-4-(isopropylthio)pyridin-2-yl)-7-formyl-6-((N-methylacetamido)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
• 英文别名: 6-[[acetyl(methyl)amino]methyl]-N-(5-cyano-4-propan-2-ylsulfanylpyridin-2-yl)-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide
• 化学式: C₂₃H₂₆N₆O₃S
• 分子量: 466.564
• InChiKey: YJWCAZSHQCOGDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  145
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
  申请人：Buschmann Nicole

  公开号：US20150119385A1

  公开（公告）日：2015-04-30

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

  本发明提供了化合物(I)或其药学上可接受的盐；制造该化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合物和包括该化合物的药物组合。
• [EN] RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS<br/>[FR] DÉRIVÉS PYRIDYLE BICYCLIQUES À ANNEAUX FUSIONNÉS UTILISÉS EN TANT QU'INHIBITEURS DE FGFR4
  申请人：NOVARTIS AG

  公开号：WO2015059668A1

  公开（公告）日：2015-04-30

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

  本发明提供了化合物(I)或其药学上可接受的盐；制备该化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合物和包含该化合物的药物组合物。
• Combinations of FGFR4 inhibitors and bile acid sequestrants
  申请人：NOVARTIS AG

  公开号：US11229643B2

  公开（公告）日：2022-01-25

  The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.

  本发明涉及一种由 FGFR4 抑制剂和胆汁酸螯合剂组成的药物组合，涉及该药物组合在癌症治疗中的应用，涉及使用胆汁酸螯合剂减少或减轻与 FGFR4 抑制疗法相关的副作用。
• RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
  申请人：Novartis AG

  公开号：EP3060563A1

  公开（公告）日：2016-08-31
• COMBINATIONS OF FGFR4 INHIBITORS AND BILE ACID SEQUESTRANTS
  申请人：Novartis AG

  公开号：EP3534902B1

  公开（公告）日：2022-11-23